NULISA CNS Disease Biomarker Platform – The Only High- Plex, High Sensitivity Platform for Investigation of Biomarkers of Neurodegenerative Diseases & Treatment Response
- NULISA™ combines ultra-sensitive femtogram level detection with barcode-based high-plex biomarker analysis.
- The NULISA CNS Disease Panel is unique in enabling investigation of hundreds of proteins involved in neuroinflammation, vascular, and synaptic dysfunction, and proteinopathies
- NULISA enables the unique ability to translate discoveries based on broad profiling into single and low-plex biomarker assays on the same instrumentation
- NULISA single-, low-, and high-plex assays all run fully automated on the ARGO HT System
- NULISA CNS Disease Panel 120 and Inflammation Panel 250 support exploratory clinical research into therapeutic effects on neurodegenerative disease processes
- NULISA IVD and ARGO DX in development with funding from Gates Ventures and DxA